Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:45 PM
Ignite Modification Date:
2025-12-24 @ 5:45 PM
NCT ID:
NCT04510168
Eligibility Criteria:
Inclusion Criteria:
* Age 50 and older
* Being part of the NOMAS MRI substudy
* Subjects unable to provide informed consent must have a surrogate decision maker
* Written and oral fluency in English or Spanish
* Able to participate in all scheduled evaluations and to complete all required tests and procedures.
* In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.
Exclusion Criteria:
* Past or present history of certain brain disorders other than Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD) (self-reported brain tumor, dementia of Lewy body, frontotemporal dementia).
* Certain significant medical conditions, which make study procedures of the current study unsafe (liver cirrhosis, end-stage renal disease on dialysis, terminal cancer (death expected within 6 months)).
* Contraindication to MRI scanning
* Conditions precluding entry into the scanners (e.g., morbid obesity, claustrophobia, etc.).
* Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits.
* Participation in a clinical trial for a disease-modifying drug for AD the year prior to the date of the first PET scan.
* Inability to have a catheter in subject's vein for the injection of radioligand.
* Inability to have blood drawn from subject's veins.
* Subjects will not be included in the study if they have participated in the last year in a clinical trial for a disease-modifying drug for AD.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT04510168
Study Brief:
Protocol Section:
NCT04510168